Table 4.
Effects of EPA on blood fatty acids composition.
| Normolipidemic (n = 18) | Hyperlipidemic (n = 16) |
||||
|---|---|---|---|---|---|
| 0M | 1M | 3M | |||
| Myristic, C14:0 | μg/mL | 21 ± 12 | 31 ± 11 | 33 ± 19 | 32 ± 19 |
| Palmitic, C16:0 | μg/mL | 668 ± 156 | 989 ± 265* | 986 ± 404* | 913 ± 390 |
| Palmitoleic, C16:1n-7 | μg/mL | 52 ± 15 | 82 ± 38* | 88 ± 52 | 79 ± 49 |
| Stearic, C18:0 | μg/mL | 221 ± 41 | 272 ± 66* | 273 ± 70* | 265 ± 68 |
| Oleic, C18:1n-9 | μg/mL | 617 ± 177 | 907 ± 249** | 856 ± 439 | 783 ± 410 |
| Linoleic, LA C18:2n-6 | μg/mL | 935 ± 200 | 1203 ± 228** | 1060 ± 248 | 996 ± 222† |
| γ-Linolenic, GLA C18:3n-6 | μg/mL | 8.3 ± 5.6 | 11.7 ± 4.0 | 8.8 ± 2.8 | 8.3 ± 3.7† |
| α-Linolenic acid, ALA C18:3n-3 | μg/mL | 27 ± 21 | 38 ± 15 | 37 ± 14 | 37 ± 15 |
| Dihomo-γ-linolenic acid, DHGLA C20:3n-6 | μg/mL | 34 ± 10 | 52 ± 15** | 35 ± 13†† | 32 ± 10††† |
| Arachidonic acid, AA C20:4n-6 | μg/mL | 182 ± 41 | 209 ± 40 | 197 ± 45 | 164 ± 45† |
| Eicosapentaenoic, EPA C20:5n-3 | μg/mL | 45 ± 26 | 52 ± 26 | 161 ± 49∗∗∗††† | 180 ± 55∗∗∗††† |
| Docosahexaenoic, DHA C22:6n-3 | μg/mL | 122 ± 46 | 159 ± 60 | 162 ± 68 | 157 ± 65 |
| EPA/AA | 0.24 ± 0.12 | 0.25 ± 0.12 | 0.84 ± 0.29∗∗∗††† | 1.16 ± 0.46∗∗∗††† | |
Mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 versus normolipidemic, † P < 0.05, ††† P < 0.001 versus 0M. 0M, 1M, and 3M: baseline and 1 and 3 months after EPA treatment.